期刊
FRONTIERS IN ONCOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.1020400
关键词
colorectal cancer; immunotherapy; chemokines; CCL5; the tumor microenvironment
类别
资金
- Science and Technology Department of National Natural Science Foundation of China [82060525, 81860100, 202002AA100007]
- Yunnan Province [202001AS070004, 2019PT310003, 202101AY070001 -126, 2020DAMARA-005]
- Yunnan Province Intelligent Talent Platform [RLMY20200019]
- Yunnan Provincial Health and Health Commission [202005AF150090, YNWR-QNBJ-2019-243, 202005AC160057, H-2018062]
Colorectal cancer is a significant global cause of cancer death, and immunotherapy using CCL5 as a potential target shows promise in improving treatment outcomes for CRC patients.
Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide, with high morbidity and mortality rates worldwide. Therefore, there is an urgent need to develop more effective treatments for CRC patients. In recent years, there has been some success in the immunotherapy of tumors, and immunotherapy has been used in many solid tumors including CRC. To date, the clinical efficacy of immunotherapy for CRC is limited, so more effective immunotherapy methods need to be explored. In patients with CRC, the CC chemokine CCL5 plays a role in the development of CRC and the recruitment and activation of immune cells, suggesting that it has potential for immunotherapy. This review mainly introduces the latest advances in the study of CCL5 acting as a marker of CRC and related mechanisms of immunotherapy, as well as the latest understanding of how CCL5 is involved in the invasion and development of CRC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据